APA (7th ed.) Citation

SE, A., N, H., C, P., TO, G., J, M., S, K., . . . RD, H. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet (London, England), 393(10184), 1948. https://doi.org/10.1016/S0140-6736(18)32557-1

Chicago Style (17th ed.) Citation

SE, Al-Batran, et al. "Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial." Lancet (London, England) 393, no. 10184 (2019): 1948. https://doi.org/10.1016/S0140-6736(18)32557-1.

MLA (9th ed.) Citation

SE, Al-Batran, et al. "Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial." Lancet (London, England), vol. 393, no. 10184, 2019, p. 1948, https://doi.org/10.1016/S0140-6736(18)32557-1.